Tredje AP fonden Acquires Shares of 15492 Bioverativ Inc (NASDAQ:BIVV)

Maricruz Casares
Diciembre 27, 2017

Can owned approximately 0.08% of Bioverativ at the end of the most recent reporting period. Canada Pension Plan Investment Board purchased a new position in shares of Bioverativ during the 3rd quarter worth about $194,000. Advisors Asset Management Inc. acquired a new stake in shares of Bioverativ during the 3rd quarter worth about $137,000. Catalyst Capital Advisors LLC purchased a new stake in shares of Bioverativ during the third quarter valued at approximately $5,707,000. ACG Wealth purchased a new stake in Bioverativ during the third quarter valued at approximately $205,000. BP PLC purchased a new position in Bioverativ in the third quarter valued at approximately $799,000. Institutional investors and hedge funds own 95.99% of the company's stock.

Shares of Bioverativ Inc (BIVV) opened at $54.04 on Tuesday. Bioverativ Inc. (NasdaqGS:BIVV) presently has a 10 month price index of 1.06044. The biotechnology company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.55 by $0.25. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The firm had revenue of $291.60 million for the quarter, compared to analysts' expectations of $285.45 million. The business's revenue for the quarter was up 27.2% on a year-over-year basis. research analysts predict that Bioverativ Inc will post 2.45 EPS for the current fiscal year.

A number of analysts recently issued reports on the company. (NasdaqGS:BIVV) is 13.192961. This ratio is found by taking the current share price and dividing by earnings per share. Piper Jaffray Companies reissued an "overweight" rating and issued a $71.00 target price on shares of Bioverativ in a research report on Monday, October 23rd. Royal Bank of Canada initiated coverage on shares of Bioverativ in a report on Thursday, September 14th. They issued a "sector perform" rating and a $59.00 target price for the company. Zacks Investment Research raised shares of Bioverativ from a "hold" rating to a "strong-buy" rating and set a $69.00 price target for the company in a report on Thursday, October 19th. Morgan Stanley reaffirmed an "underweight" rating and issued a $47.00 price objective (up previously from $45.00) on shares of Bioverativ in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, nine have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock.

More news: Edgar Lomax Co Cut Allstate Corporation (ALL) Stake as Stock Value Rose

TRADEMARK VIOLATION WARNING: This report was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of United States & global copyright & trademark laws. The correct version of this piece of content can be viewed at https://stocknewstimes.com/2017/12/26/public-employees-retirement-system-of-ohio-purchases-shares-of-85053-bioverativ-inc-bivv.html.

The Price to Cash Flow for Bioverativ Inc. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It is also developing BIVV 001 (rFVIIIFc-VWF-XTEN), a preclinical program of the combination of factor VIII-Fc fusion protein for the treatment of hemophilia A; BIVV 002 (rFIXFc-XTEN), a preclinical program for a recombinant factor IX replacement product for the treatment of patients with hemophilia B; and Bi-Specific antibody program, a preclinical program to develop a non-factor bi-specific antibody for the treatment of patients with hemophilia A. On the other hand, company insiders are holding 0.10%.

Otros informes por

Discuta este artículo

SIGUE NUESTRO PERIÓDICO